Mar 12, 2026 7:30am EDT Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
Mar 06, 2026 7:47am EST Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Jan 13, 2026 7:47am EST Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
Dec 11, 2025 7:47am EST Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
Dec 05, 2025 7:30am EST Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
Dec 04, 2025 7:47am EST Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
Nov 06, 2025 4:02pm EST Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Oct 31, 2025 8:00am EDT Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
Oct 30, 2025 7:30am EDT Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
